While companies developing solutions that address the current pandemic may be receiving an influx of financial support, recovery for companies in other segments of the industry is slow.
With the rapid growth of life tech discoveries, there is a need to adapt the patent and regulatory frameworks governing the approval, use, and protection of such discoveries.
Augmented reality and extended reality will play a front-and-center role in patient care.
Artificial intelligence and machine learning are proving to be meaningful weapons in our arsenal during the coronavirus crisis.
The Chinese government is investing heavily in the development of new technologies that leverage AI. This includes solutions to address the COVID-19 outbreak.
Personalized medicine is the future of healthcare, and artificial intelligence will play a big role.
Treatment can no longer be one dimensional.
Medical device companies will be driven to evolve their business models to a more patient/consumer-centric approach.
After a series of delays and false starts, EMA is now progressing its ISO IDMP agenda with firm intent. The first implementation guide is out now for consultation, to be followed by a second actionable version by next year. Life sciences companies targeting Europe will have a year to comply with all the measures—but this will be a lot of work.
A recent report from Frost & Sullivan anticipates strong market growth but also points to opportunity for more vulnerabilities.
